PHOTOSTIMULATION OF LYMPHATIC CLEARANCE OFβ-AMYLOID FROM MOUSE BRAIN: NEW STRATEGY FOR THE THERAPY OF ALZHEIMER’S DISEASE
Semyachkina-Glushkovskaya Oxana V. - Doctor of Biological Sciences, Associate Professor, Head of the Department of Human and Animal Physiology, Saratov National Research State University named after N.G. Chernyshevsky, Russian Federation, 410012, Saratov, Astrakhanskaya str., 83, glushkovskaya@mail.ru
Sarantseva Elena Ivanovna - candidate of biological sciences, Associate Professor, Department of Human and Animal Physiology, Saratov National Research State University named after N.G. Chernyshevsky, Russin Federation, 410012, Saratov, st. Astrakhanskaya, 83, sophora@mail.ru
Iskra Tatyana Dmitrievna - candidate of biological sciences, Associate Professor, Department of Human and Animal Physiology, Saratov National Research State University named after N.G. Chernyshevsky, Russian Federation, 410012, Saratov, st. Astrakhanskaya, 83, tata-isk@yandex.ru
Alzheimer's disease (AD) is an age-related neurodegenerative disease that causes a decline in cognitive functions such as memory, intelligence, and speech. AD is a significant medical problem in modern society, due to the ineffective available therapeutic technologies. New strategies are needed to improve brain clearance of β-amyloid (Aβ) protein. Photobiomodulation (PBM) is an effective, non-invasive therapeutic modality that holds great promise in the treatment of many brain diseases. The data obtained from the pilot study showed that PBM safely accelerates the lymphatic clearance of the brain of 5xFADAD mice from Aβ, stimulates the meningeal lymphatic vessels pathway, with a certain degree of specificity in different areas of the brain, and improves the cognitive functions of animals with AD. Our results indicate that FBM has high potential as an effective therapeutic agent for AD.
Key words: Alzheimer's disease, photobiomodulation, brain diseases, lymphatic clearance, β-amyloid, cognitive functions